The Threat of Carbapenem-Resistant Gram-Negative Bacteria in Patients with Hematological Malignancies: Unignorable Respiratory Non-Fermentative Bacteria-Derived Bloodstream Infections

References

• Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl Supplement_7):S521–S528. doi:10.1093/cid/ciz824
   Web of Science ®Google Scholar
• Lalaoui R, Javelle E, Bakour S, Ubeda C, Rolain JM. Infections due to carbapenem-resistant bacteria in patients with hematologic malignancies. Front Microbiol. 2020;11:1422. doi:10.3389/fmicb.2020.01422
   PubMed Web of Science ®Google Scholar
• Andria N, Henig O, Kotler O, et al. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study. J Antimicrob Chemother. 2015;70(11):3146–3153. doi:10.1093/jac/dkv218
   PubMed Web of Science ®Google Scholar
• Kara Ali R, Surme S, Balkan II, et al. An eleven-year cohort of bloodstream infections in 552 febrile neutropenic patients: resistance profiles of Gram-negative bacteria as a predictor of mortality. Ann Hematol. 2020;99(8):1925–1932. doi:10.1007/s00277-020-04144-wF
   Web of Science ®Google Scholar
• Li Y, Sun QL, Shen Y, et al. Rapid Increase in Prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) and emergence of colistin resistance Gene mcr-1 in CRE in a Hospital in Henan, China. J Clin Microbiol. 2018;56(4). doi:10.1128/jcm.01932-17
   Web of Science ®Google Scholar
• Chen J, Hu C, Wang R, et al. Shift in the dominant sequence type of carbapenem-resistant Klebsiella pneumoniae bloodstream infection from ST11 to ST15 at a Medical Center in Northeast China, 2015–2020. Infect Drug Resist. 2021;14:1855–1863. doi:10.2147/IDR.S311968
   Web of Science ®Google Scholar
• Liang C, Zhang X, Zhou L, Meng G, Zhong L, Peng P. Trends and correlation between antibacterial consumption and carbapenem resistance in gram-negative bacteria in a tertiary hospital in China from 2012 to 2019. BMC Infect Dis. 2021;21(1):444. doi:10.1186/s12879-021-06140-5
   PubMed Web of Science ®Google Scholar
• Caston JJ, Lacort-Peralta I, Martin-Davila P, et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017;59:118–123. doi:10.1016/j.ijid.2017.03.021
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Cohen N, Ma KC, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect. 2016;73(4):336–345. doi:10.1016/j.jinf.2016.07.002
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics.2017. Available from: http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. Accessed February 1, 2019.
   Google Scholar
• Tang Y, Xu C, Xiao H, Wang L, Cheng Q, Li X. Gram-negative bacteria bloodstream infections in patients with hematological malignancies – the impact of pathogen type and patterns of antibiotic resistance: a Retrospective Cohort Study. Infect Drug Resist. 2021;14:3115–3124. doi:10.2147/IDR.S322812
   Web of Science ®Google Scholar
• Scheich S, Weber S, Reinheimer C, et al. Bloodstream infections with gram-negative organisms and the impact of multidrug resistance in patients with hematological malignancies. Ann Hematol. 2018;97(11):2225–2234. doi:10.1007/s00277-018-3423-5
   Web of Science ®Google Scholar
• Yang -T-T, Luo X-P, Yang Q, et al. Different screening frequencies of carbapenem-resistant Enterobacteriaceae in patients undergoing hematopoietic stem cell transplantation: which one is better? Antimicrob Resist Infect Control. 2020;9(1):49. doi:10.1186/s13756-020-0706-0
   Web of Science ®Google Scholar
• Richter SS, Marchaim D. Screening for carbapenem-resistant Enterobacteriaceae: who, when, and how? Virulence. 2017;8(4):417–426. doi:10.1080/21505594.2016.1255381
   PubMed Web of Science ®Google Scholar
• Garpvall K, Duong V, Linnros S, et al. Admission screening and cohort care decrease carbapenem resistant Enterobacteriaceae in Vietnamese pediatric ICU’s. Antimicrob Resist Infect Control. 2021;10(1):128. doi:10.1186/s13756-021-00994-9
   PubMed Web of Science ®Google Scholar
• Lima EM, Cid PA, Beck DS, et al. Predictive factors for sepsis by carbapenem resistant Gram-negative bacilli in adult critical patients in Rio de Janeiro: a case-case-control design in a prospective cohort study. Antimicrob Resist Infect Control. 2020;9(1):132. doi:10.1186/s13756-020-00791-w
   Web of Science ®Google Scholar
• Routsi C, Pratikaki M, Platsouka E, et al. Risk factors for carbapenem-resistant Gram-negative bacteremia in intensive care unit patients. Intensive Care Med. 2013;39(7):1253–1261. doi:10.1007/s00134-013-2914-z
   PubMed Web of Science ®Google Scholar
• Bao H, Qiao Y, Liu D, et al. The clinical impact of Stenotrophomonas maltophilia bacteremia on the 30-day mortality rate in patients with hematologic disorders: a single-institution experience. Infection. 2020;48(2):205–212. doi:10.1007/s15010-019-01369-4
   PubMed Web of Science ®Google Scholar
• Shargian-Alon L, Gafter-Gvili A, Ben-Zvi H, et al. Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies – a retrospective study. Leuk Lymphoma. 2019;60(11):2787–2792. doi:10.1080/10428194.2019.1599113
   PubMed Web of Science ®Google Scholar
• Aviv T, Lazarovitch T, Katz D, et al. The epidemiological impact and significance of carbapenem resistance in Pseudomonas aeruginosa bloodstream infections: a matched case-case-control analysis. Infect Control Hosp Epidemiol. 2018;39(10):1262–1265. doi:10.1017/ice.2018.181
   Web of Science ®Google Scholar
• Amat T, Gutierrez-Pizarraya A, Machuca I, et al. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2018;24(6):630–634. doi:10.1016/j.cmi.2017.09.016
   PubMed Web of Science ®Google Scholar
• Britt NS, Ritchie DJ, Kollef MH, et al. Importance of site of infection and antibiotic selection in the treatment of carbapenem-resistant pseudomonas aeruginosa sepsis. Antimicrob Agents Chemother. 2018;62(4). doi:10.1128/aac.02400-17
   Web of Science ®Google Scholar
• Freire MP, de Oliveira Garcia D, Garcia CP, et al. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect. 2016;22(4):352–358. doi:10.1016/j.cmi.2015.12.010
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hematology CMA, Chinese Medical Doctor Association HB. [Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2020)]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(12):969–978. Chinese. doi:10.3760/cma.j.issn.0253-2727.2020.12.001
   Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98(12):1826–1835. doi:10.3324/haematol.2013.091025
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Facility guidance for control of carbapenem- resistant Enterobacteriaceae (CRE) 2015 update [S/OL]; 2015. Available from: https://www.cdc.gov/. Accessed May 17, 2022.
   Google Scholar
• Genga KR, Russell JA. Update of sepsis in the intensive care unit. J Innate Immun. 2017;9(5):441–455. doi:10.1159/000477419
   PubMed Web of Science ®Google Scholar
• Tang Y, Wu X, Cheng Q, Li X. Inappropriate initial antimicrobial therapy for hematological malignancies patients with Gram-negative bloodstream infections. Infection. 2020;48(1):109–116. doi:10.1007/s15010-019-01370-x
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56–93. doi:10.1093/cid/cir073
   PubMed Web of Science ®Google Scholar
• Tang Y, Cheng Q, Yang Q, et al. Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections. Infection. 2018;46(4):513–521. doi:10.1007/s15010-018-1151-3
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lin Q, Liu L, et al. Risk factors and outcomes of antibiotic-resistant pseudomonas aeruginosa bloodstream infection in adult patients with acute leukemia. Clin Infect Dis. 2020;71(Suppl 4):S386–S393. doi:10.1093/cid/ciaa1522
   PubMed Web of Science ®Google Scholar
• Sartelli M, Guirao X, Hardcastle TC, et al. 2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World J Emerg Surg. 2018;13:58. doi:10.1186/s13017-018-0219-9
   PubMed Web of Science ®Google Scholar
• Tamma PD, Goodman KE, Harris AD, et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis. 2017;64(3):257–264. doi:10.1093/cid/ciw741
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Martino B, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91(11):1076–1081. doi:10.1002/ajh.24489
   PubMed Web of Science ®Google Scholar
• Tofas P, Skiada A, Angelopoulou M, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases. Int J Antimicrob Agents. 2016;47(4):335–339. doi:10.1016/j.ijantimicag.2016.01.011
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang L, Sun A, et al. Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the infection working party of Jiangsu society of hematology. Eur J Clin Microbiol Infect Dis. 2017;36(7):1073–1081. doi:10.1007/s10096-016-2895-2
   PubMed Web of Science ®Google Scholar
• Palacios-Baena ZR, Giannella M, Manissero D, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clin Microbiol Infect. 2021;27(2):228–235. doi:10.1016/j.cmi.2020.10.016
   PubMed Web of Science ®Google Scholar
• Wanla W, Katip W, Supakul S, Apiwatnakorn P, Khamsarn S. Effects of an antimicrobial restriction system on appropriate carbapenem use in a hospital without infectious diseases consultation. Int J Gen Med. 2017;10:443–449. doi:10.2147/IJGM.S145133
   PubMed Web of Science ®Google Scholar
• Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis. 2017;17(1):203. doi:10.1186/s12879-017-2297-9
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hematology CMA, Chinese Hematology Association CMDA. [Management of Carbapenem-resistant Enterobacteriaceae (CRE) infection in patients with hematological malignancies: Chinese consensus (2020)]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(11):881–889. Chinese. doi:10.3760/cma.j.issn.0253-2727.2020.11.001
   Google Scholar
• Girmenia C, Viscoli C, Piciocchi A, et al. Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. Haematologica. 2015;100(9):e373–6. doi:10.3324/haematol.2015.125484
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF, Novel A. Algorithm to analyze epidemiology and outcomes of carbapenem resistance among patients with hospital-acquired and ventilator-associated pneumonia: a retrospective cohort study. Chest. 2019;155(6):1119–1130. doi:10.1016/j.chest.2018.12.024
   PubMed Web of Science ®Google Scholar
• Berube BJ, Rangel SM, Hauser AR. Pseudomonas aeruginosa: breaking down barriers. Curr Genet. 2016;62(1):109–113. doi:10.1007/s00294-015-0522-x
   PubMed Web of Science ®Google Scholar
• Li H, Zhang J, Wang Z, et al. Evolution of Acinetobacter baumannii in clinical bacteremia patients. Infect Drug Resist. 2021;14:3553–3562. doi:10.2147/IDR.S320645
   Web of Science ®Google Scholar
• Cai B, Tillotson G, Benjumea D, Callahan P, Echols R. The burden of bloodstream infections due to stenotrophomonas maltophilia in the United States: a large, retrospective database study. Open Forum Infect Dis. 2020;7(5):ofaa141. doi:10.1093/ofid/ofaa141
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients. Pharmaceutics. 2021;14(1). doi:10.3390/pharmaceutics14010031
   Web of Science ®Google Scholar
• Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant Acinetobacter baumannii: a propensity score-matched analysis. Pharmaceutics. 2021;13(2). doi:10.3390/pharmaceutics13020162
   Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients: a propensity score-matched analysis. Antibiotics. 2020;9(10). doi:10.3390/antibiotics9100647
   Web of Science ®Google Scholar